Skip to main content

Advertisement

SpringerLink
Log in

Rethinking Bile Acid Metabolism and Signaling for Type 2 Diabetes Treatment

  • Pathogenesis of Type 2 Diabetes and Insulin Resistance (M-E Patti, Section Editor)
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Herein, we review the role of FXR and TGR5 in the regulation of hepatic bile acid metabolism, with a focus on how our understanding of bile acid metabolic regulation by these receptors has evolved in recent years and how this improved understanding may facilitate targeting bile acids for type 2 diabetes treatment.

Recent Findings

Bile acid profile is a key regulator of metabolic homeostasis. Inhibition of expression of the enzyme that is required for cholic acid synthesis and thus determines bile acid profile, Cyp8b1, may be an effective target for type 2 diabetes treatment. FXR and, more recently, TGR5 have been shown to regulate bile acid metabolism and Cyp8b1 expression and, therefore, may provide a mechanism with which to target bile acid profile for type 2 diabetes treatment.

Summary

Inhibition of Cyp8b1 expression is a promising therapeutic modality for type 2 diabetes; however, further work is needed to fully understand the pathways regulating Cyp8b1 expression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89(1):147–91. https://doi.org/10.1152/physrev.00010.2008.

    Article  CAS  PubMed  Google Scholar 

  2. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov. 2008;7(8):678–93. https://doi.org/10.1038/nrd2619.

    Article  CAS  PubMed  Google Scholar 

  3. Haeusler RA, Astiarraga B, Camastra S, Accili D, Ferrannini E. Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids. Diabetes. 2013;62(12):4184–91. https://doi.org/10.2337/db13-0639.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Heuman DM. Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J Lipid Res. 1989;30(5):719–30.

    CAS  PubMed  Google Scholar 

  5. Mahmoud AA, Elshazly SM. Ursodeoxycholic acid ameliorates fructose-induced metabolic syndrome in rats. PLoS One. 2014;9(9):e106993. https://doi.org/10.1371/journal.pone.0106993.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313(5790):1137–40. https://doi.org/10.1126/science.1128294.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Shima KR, Ota T, Kato KI, Takeshita Y, Misu H, Kaneko S, et al. Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study. BMJ Open Diabetes Res Care. 2018;6(1):e000469. https://doi.org/10.1136/bmjdrc-2017-000469.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Cariou B, Chetiveaux M, Zair Y, Pouteau E, Disse E, Guyomarc'h-Delasalle B, et al. Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults. Nutr Metab (Lond). 2011;8(1):48. https://doi.org/10.1186/1743-7075-8-48.

    Article  CAS  Google Scholar 

  9. Chung SJ, Lee CH, Lee HS, Kim ST, Sohn UD, Park ES, et al. The role of phosphatidylcholine and deoxycholic acid in inflammation. Life Sci. 2014;108(2):88–93. https://doi.org/10.1016/j.lfs.2014.05.013.

    Article  CAS  PubMed  Google Scholar 

  10. Zaborska KE, Lee SA, Garribay D, Cha E, Cummings BP. Deoxycholic acid supplementation impairs glucose homeostasis in mice. PLoS One. 2018;13(7):e0200908. https://doi.org/10.1371/journal.pone.0200908.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Bertaggia E, Jensen KK, Castro-Perez J, Xu Y, Di Paolo G, Chan RB, et al. Cyp8b1 ablation prevents Western diet-induced weight gain and hepatic steatosis because of impaired fat absorption. Am J Physiol Endocrinol Metab. 2017;313(2):E121–33. https://doi.org/10.1152/ajpendo.00409.2016.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Li-Hawkins J, Gafvels M, Olin M, Lund EG, Andersson U, Schuster G, et al. Cholic acid mediates negative feedback regulation of bile acid synthesis in mice. J Clin Invest. 2002;110(8):1191–200. https://doi.org/10.1172/JCI16309.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Murphy C, Parini P, Wang J, Bjorkhem I, Eggertsen G, Gafvels M. Cholic acid as key regulator of cholesterol synthesis, intestinal absorption and hepatic storage in mice. Biochim Biophys Acta. 2005;1735(3):167–75. https://doi.org/10.1016/j.bbalip.2005.06.001.

    Article  CAS  PubMed  Google Scholar 

  14. Slatis K, Gafvels M, Kannisto K, Ovchinnikova O, Paulsson-Berne G, Parini P, et al. Abolished synthesis of cholic acid reduces atherosclerotic development in apolipoprotein E knockout mice. J Lipid Res. 2010;51(11):3289–98. https://doi.org/10.1194/jlr.M009308.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Wang J, Gafvels M, Rudling M, Murphy C, Bjorkhem I, Einarsson C, et al. Critical role of cholic acid for development of hypercholesterolemia and gallstones in diabetic mice. Biochem Biophys Res Commun. 2006;342(4):1382–8. https://doi.org/10.1016/j.bbrc.2006.02.108.

    Article  CAS  PubMed  Google Scholar 

  16. • McGavigan AK, Garibay D, Henseler ZM, Chen J, Bettaieb A, Haj FG, et al. TGR5 contributes to glucoregulatory improvements after vertical sleeve gastrectomy in mice. Gut. 2017;66(2):226–34. https://doi.org/10.1136/gutjnl-2015-309871 This study identifies a role for TGR5 in the regulation of hepatic CYP8B1 expression.

    Article  CAS  PubMed  Google Scholar 

  17. • Pathak P, Liu H, Boehme S, Xie C, Krausz KW, Gonzalez F, et al. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism. J Biol Chem. 2017;292(26):11055–69. https://doi.org/10.1074/jbc.M117.784322 This study provides the first description of an interation between TGR5 and FXR.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Pean N, Doignon I, Garcin I, Besnard A, Julien B, Liu B, et al. The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice. Hepatology. 2013;58(4):1451–60. https://doi.org/10.1002/hep.26463.

    Article  CAS  PubMed  Google Scholar 

  19. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003;72:137–74. https://doi.org/10.1146/annurev.biochem.72.121801.161712.

    Article  CAS  PubMed  Google Scholar 

  20. He D, Barnes S, Falany CN. Rat liver bile acid CoA:amino acid N-acyltransferase: expression, characterization, and peroxisomal localization. J Lipid Res. 2003;44(12):2242–9. https://doi.org/10.1194/jlr.M300128-JLR200.

    Article  CAS  PubMed  Google Scholar 

  21. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. Curr Opin Gastroenterol. 2014;30(3):332–8. https://doi.org/10.1097/MOG.0000000000000057.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Zhang Y, Klaassen CD. Effects of feeding bile acids and a bile acid sequestrant on hepatic bile acid composition in mice. J Lipid Res. 2010;51(11):3230–42. https://doi.org/10.1194/jlr.M007641.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Hagey LR, Crombie DL, Espinosa E, Carey MC, Igimi H, Hofmann AF. Ursodeoxycholic acid in the Ursidae: biliary bile acids of bears, pandas, and related carnivores. J Lipid Res. 1993;34(11):1911–7.

    CAS  PubMed  Google Scholar 

  24. Bachrach WH, Hofmann AF. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. part I. Dig Dis Sci. 1982;27(8):737–61.

    Article  CAS  PubMed  Google Scholar 

  25. Fedorowski T, Salen G, Tint GS, Mosbach E. Transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal bacteria. Gastroenterology. 1979;77(5):1068–73.

    CAS  PubMed  Google Scholar 

  26. Ferdinandusse S, Houten SM. Peroxisomes and bile acid biosynthesis. Biochim Biophys Acta. 2006;1763(12):1427–40. https://doi.org/10.1016/j.bbamcr.2006.09.001.

    Article  CAS  PubMed  Google Scholar 

  27. Chiang JY. Regulation of bile acid synthesis. Front Biosci. 1998;3:d176–93.

    Article  CAS  PubMed  Google Scholar 

  28. Norlin M, Wikvall K. Enzymes in the conversion of cholesterol into bile acids. Curr Mol Med. 2007;7(2):199–218.

    Article  CAS  PubMed  Google Scholar 

  29. Wu Z, Martin KO, Javitt NB, Chiang JY. Structure and functions of human oxysterol 7alpha-hydroxylase cDNAs and gene CYP7B1. J Lipid Res. 1999;40(12):2195–203.

    CAS  PubMed  Google Scholar 

  30. Andersson S, Davis DL, Dahlback H, Jornvall H, Russell DW. Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J Biol Chem. 1989;264(14):8222–9.

    CAS  PubMed  Google Scholar 

  31. Preuss I, Ludwig MG, Baumgarten B, Bassilana F, Gessier F, Seuwen K, et al. Transcriptional regulation and functional characterization of the oxysterol/EBI2 system in primary human macrophages. Biochem Biophys Res Commun. 2014;446(3):663–8. https://doi.org/10.1016/j.bbrc.2014.01.069.

    Article  CAS  PubMed  Google Scholar 

  32. Reiss AB, Martin KO, Rojer DE, Iyer S, Grossi EA, Galloway AC, et al. Sterol 27-hydroxylase: expression in human arterial endothelium. J Lipid Res. 1997;38(6):1254–60.

    CAS  PubMed  Google Scholar 

  33. Schwarz M, Lund EG, Lathe R, Bjorkhem I, Russell DW. Identification and characterization of a mouse oxysterol 7alpha-hydroxylase cDNA. J Biol Chem. 1997;272(38):23995–4001..

    Article  CAS  PubMed  Google Scholar 

  34. Shanahan CM, Carpenter KL, Cary NR. A potential role for sterol 27-hydroxylase in atherogenesis. Atherosclerosis. 2001;154(2):269–76.

    Article  CAS  PubMed  Google Scholar 

  35. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 1995;81(5):687–93.

    Article  CAS  PubMed  Google Scholar 

  36. Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res. 2010;51(4):771–84. https://doi.org/10.1194/jlr.M001602.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. De Gottardi A, Touri F, Maurer CA, Perez A, Maurhofer O, Ventre G, et al. The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig Dis Sci. 2004;49(6):982–9.

    Article  PubMed  Google Scholar 

  38. Raybould HE. Gut microbiota, epithelial function and derangements in obesity. J Physiol. 2012;590(3):441–6. https://doi.org/10.1113/jphysiol.2011.222133.

    Article  CAS  PubMed  Google Scholar 

  39. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284(5418):1362–5.

    Article  CAS  PubMed  Google Scholar 

  40. Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell. 1999;3(5):543–53.

    Article  CAS  PubMed  Google Scholar 

  41. Li Y, Jadhav K, Zhang Y. Bile acid receptors in non-alcoholic fatty liver disease. Biochem Pharmacol. 2013;86(11):1517–24. https://doi.org/10.1016/j.bcp.2013.08.015.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Li F, Jiang C, Krausz KW, Li Y, Albert I, Hao H, et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun. 2013;4:2384. https://doi.org/10.1038/ncomms3384.

    Article  CAS  PubMed  Google Scholar 

  43. Parseus A, Sommer N, Sommer F, Caesar R, Molinaro A, Stahlman M, et al. Microbiota-induced obesity requires farnesoid X receptor. Gut. 2017;66(3):429–37. https://doi.org/10.1136/gutjnl-2015-310283.

    Article  CAS  PubMed  Google Scholar 

  44. Sayin SI, Wahlstrom A, Felin J, Jantti S, Marschall HU, Bamberg K, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013;17(2):225–35. https://doi.org/10.1016/j.cmet.2013.01.003.

    Article  CAS  PubMed  Google Scholar 

  45. Mueller M, Thorell A, Claudel T, Jha P, Koefeler H, Lackner C, et al. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J Hepatol. 2015;62(6):1398–404. https://doi.org/10.1016/j.jhep.2014.12.034.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem. 2006;281(16):11039–49. https://doi.org/10.1074/jbc.M510258200.

    Article  CAS  PubMed  Google Scholar 

  47. Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology. 2004;127(5):1497–512.

    Article  CAS  PubMed  Google Scholar 

  48. Fiorucci S, Rizzo G, Donini A, Distrutti E, Santucci L. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med. 2007;13(7):298–309. https://doi.org/10.1016/j.molmed.2007.06.001.

    Article  CAS  PubMed  Google Scholar 

  49. Mencarelli A, Renga B, D'Amore C, Santorelli C, Graziosi L, Bruno A, et al. Dissociation of intestinal and hepatic activities of FXR and LXRalpha supports metabolic effects of terminal ileum interposition in rodents. Diabetes. 2013;62(10):3384–93. https://doi.org/10.2337/db13-0299.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Swanson HI, Wada T, Xie W, Renga B, Zampella A, Distrutti E, et al. Role of nuclear receptors in lipid dysfunction and obesity-related diseases. Drug Metab Dispos. 2013;41(1):1–11. https://doi.org/10.1124/dmd.112.048694.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  51. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A. 2006;103(4):1006–11. https://doi.org/10.1073/pnas.0506982103.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  52. Dufer M, Horth K, Wagner R, Schittenhelm B, Prowald S, Wagner TF, et al. Bile acids acutely stimulate insulin secretion of mouse beta-cells via farnesoid X receptor activation and K(ATP) channel inhibition. Diabetes. 2012;61(6):1479–89. https://doi.org/10.2337/db11-0815.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  53. Potthoff MJ, Boney-Montoya J, Choi M, He T, Sunny NE, Satapati S, et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab. 2011;13(6):729–38. https://doi.org/10.1016/j.cmet.2011.03.019.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  54. Jiang C, Xie C, Li F, Zhang L, Nichols RG, Krausz KW, et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest. 2015;125(1):386–402. https://doi.org/10.1172/JCI76738.

    Article  PubMed  Google Scholar 

  55. Jiang C, Xie C, Lv Y, Li J, Krausz KW, Shi J, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun. 2015;6:10166. https://doi.org/10.1038/ncomms10166.

    Article  CAS  PubMed  Google Scholar 

  56. Trabelsi MS, Daoudi M, Prawitt J, Ducastel S, Touche V, Sayin SI, et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun. 2015;6:7629. https://doi.org/10.1038/ncomms8629.

    Article  PubMed  Google Scholar 

  57. Becker-Andre M, Andre E, DeLamarter JF. Identification of nuclear receptor mRNAs by RT-PCR amplification of conserved zinc-finger motif sequences. Biochem Biophys Res Commun. 1993;194(3):1371–9.

    Article  CAS  PubMed  Google Scholar 

  58. Chiang JY, Kimmel R, Weinberger C, Stroup D. Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J Biol Chem. 2000;275(15):10918–24.

    Article  CAS  PubMed  Google Scholar 

  59. Galarneau L, Pare JF, Allard D, Hamel D, Levesque L, Tugwood JD, et al. The alpha1-fetoprotein locus is activated by a nuclear receptor of the Drosophila FTZ-F1 family. Mol Cell Biol. 1996;16(7):3853–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell. 2000;6(3):517–26.

    Article  CAS  PubMed  Google Scholar 

  61. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell. 2000;6(3):507–15.

    Article  CAS  PubMed  Google Scholar 

  62. Nitta M, Ku S, Brown C, Okamoto AY, Shan B. CPF: an orphan nuclear receptor that regulates liver-specific expression of the human cholesterol 7alpha-hydroxylase gene. Proc Natl Acad Sci U S A. 1999;96(12):6660–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Stroup D, Chiang JY. HNF4 and COUP-TFII interact to modulate transcription of the cholesterol 7alpha-hydroxylase gene (CYP7A1). J Lipid Res. 2000;41(1):1–11.

    CAS  PubMed  Google Scholar 

  64. Zhang M, Chiang JY. Transcriptional regulation of the human sterol 12alpha-hydroxylase gene (CYP8B1): roles of heaptocyte nuclear factor 4alpha in mediating bile acid repression. J Biol Chem. 2001;276(45):41690–9. https://doi.org/10.1074/jbc.M105117200.

    Article  CAS  PubMed  Google Scholar 

  65. Lee YK, Moore DD. Dual mechanisms for repression of the monomeric orphan receptor liver receptor homologous protein-1 by the orphan small heterodimer partner. J Biol Chem. 2002;277(4):2463–7. https://doi.org/10.1074/jbc.M105161200.

    Article  CAS  PubMed  Google Scholar 

  66. Yang Y, Zhang M, Eggertsen G, Chiang JY. On the mechanism of bile acid inhibition of rat sterol 12alpha-hydroxylase gene (CYP8B1) transcription: roles of alpha-fetoprotein transcription factor and hepatocyte nuclear factor 4alpha. Biochim Biophys Acta. 2002;1583(1):63–73.

    Article  CAS  PubMed  Google Scholar 

  67. Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003;17(13):1581–91. https://doi.org/10.1101/gad.1083503.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  68. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2(4):217–25. https://doi.org/10.1016/j.cmet.2005.09.001.

    Article  CAS  PubMed  Google Scholar 

  69. Kong B, Wang L, Chiang JY, Zhang Y, Klaassen CD, Guo GL. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology. 2012;56(3):1034–43. https://doi.org/10.1002/hep.25740.

    Article  CAS  PubMed  Google Scholar 

  70. Song KH, Li T, Owsley E, Strom S, Chiang JY. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology. 2009;49(1):297–305. https://doi.org/10.1002/hep.22627.

    Article  CAS  PubMed  Google Scholar 

  71. Kerr TA, Saeki S, Schneider M, Schaefer K, Berdy S, Redder T, et al. Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. Dev Cell. 2002;2(6):713–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Wang L, Lee YK, Bundman D, Han Y, Thevananther S, Kim CS, et al. Redundant pathways for negative feedback regulation of bile acid production. Dev Cell. 2002;2(6):721–31.

    Article  CAS  PubMed  Google Scholar 

  73. • Xu Y, Li F, Zalzala M, Xu J, Gonzalez FJ, Adorini L, et al. Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice. Hepatology. 2016;64(4):1072–85. https://doi.org/10.1002/hep.28712 This study provides important in vivo tissue-specific information on FXR regulation of hepatic bile acid metabolism.

    Article  CAS  PubMed  Google Scholar 

  74. de Aguiar Vallim TQ, Tarling EJ, Ahn H, Hagey LR, Romanoski CE, Lee RG, et al. MAFG is a transcriptional repressor of bile acid synthesis and metabolism. Cell Metab. 2015;21(2):298–311. https://doi.org/10.1016/j.cmet.2015.01.007.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  75. • Tarling EJ, Clifford BL, Cheng J, Morand P, Cheng A, Lester E, et al. RNA-binding protein ZFP36L1 maintains posttranscriptional regulation of bile acid metabolism. J Clin Invest. 2017;127(10):3741–54. https://doi.org/10.1172/JCI94029 This manuscript identifies an important post-transcriptional regulator of bile acid metabolism.

    Article  PubMed Central  PubMed  Google Scholar 

  76. de Aguiar Vallim TQ, Tarling EJ, Kim T, Civelek M, Baldan A, Esau C, et al. MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma high-density lipoprotein after activation of the nuclear receptor farnesoid X receptor. Circ Res. 2013;112(12):1602–12. https://doi.org/10.1161/CIRCRESAHA.112.300648.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  77. Song KH, Li T, Owsley E, Chiang JY. A putative role of micro RNA in regulation of cholesterol 7alpha-hydroxylase expression in human hepatocytes. J Lipid Res. 2010;51(8):2223–33. https://doi.org/10.1194/jlr.M004531.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  78. Li T, Francl JM, Boehme S, Chiang JY. Regulation of cholesterol and bile acid homeostasis by the cholesterol 7alpha-hydroxylase/steroid response element-binding protein 2/microRNA-33a axis in mice. Hepatology. 2013;58(3):1111–21. https://doi.org/10.1002/hep.26427.

    Article  CAS  PubMed  Google Scholar 

  79. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. The N Engl J Med. 2013;368(18):1685–94. https://doi.org/10.1056/NEJMoa1209026.

    Article  CAS  PubMed  Google Scholar 

  80. Schmidt MF. miRNA targeting drugs: the next blockbusters? Methods Mol Biol. 2017;1517:3–22. https://doi.org/10.1007/978-1-4939-6563-2_1.

    Article  CAS  PubMed  Google Scholar 

  81. Baker DM, Wang SL, Bell DJ, Drevon CA, Davis RA. One or more labile proteins regulate the stability of chimeric mRNAs containing the 3′-untranslated region of cholesterol-7alpha -hydroxylase mRNA. J Biol Chem. 2000;275(26):19985–91. https://doi.org/10.1074/jbc.M002351200.

    Article  CAS  PubMed  Google Scholar 

  82. Noshiro M, Nishimoto M, Okuda K. Rat liver cholesterol 7 alpha-hydroxylase. Pretranslational regulation for circadian rhythm. J Biol Chem. 1990;265(17):10036–41.

    CAS  PubMed  Google Scholar 

  83. Pandak WM, Stravitz RT, Lucas V, Heuman DM, Chiang JY. Hep G2 cells: a model for studies on regulation of human cholesterol 7alpha-hydroxylase at the molecular level. Am J Phys. 1996;270(3 Pt 1):G401–10. https://doi.org/10.1152/ajpgi.1996.270.3.G401.

    Article  CAS  Google Scholar 

  84. Fiorucci S, Baldelli F. Farnesoid X receptor agonists in biliary tract disease. Curr Opin Gastroenterol. 2009;25(3):252–9. https://doi.org/10.1097/MOG.0b013e328324f87e.

    Article  CAS  PubMed  Google Scholar 

  85. Fiorucci S, Distrutti E, Ricci P, Giuliano V, Donini A, Baldelli F. Targeting FXR in cholestasis: hype or hope. Expert Opin Ther Targets. 2014;18(12):1449–59. https://doi.org/10.1517/14728222.2014.956087.

    Article  CAS  PubMed  Google Scholar 

  86. Fiorucci S, Mencarelli A, Cipriani S, Renga B, Palladino G, Santucci L, et al. Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice. Br J Pharmacol. 2011;164(8):1929–38. https://doi.org/10.1111/j.1476-5381.2011.01481.x.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  87. Fiorucci S, Mencarelli A, Distrutti E, Zampella A. Farnesoid X receptor: from medicinal chemistry to clinical applications. Future Med Chem. 2012;4(7):877–91. https://doi.org/10.4155/fmc.12.41.

    Article  CAS  PubMed  Google Scholar 

  88. Sepe V, Distrutti E, Fiorucci S, Zampella A. Farnesoid X receptor modulators (2011 - 2014): a patent review. Expert Opin Ther Pat. 2015;25(8):885–96. https://doi.org/10.1517/13543776.2015.1045413.

    Article  CAS  PubMed  Google Scholar 

  89. Erickson SK, Lear SR, Deane S, Dubrac S, Huling SL, Nguyen L, et al. Hypercholesterolemia and changes in lipid and bile acid metabolism in male and female cyp7A1-deficient mice. J Lipid Res. 2003;44(5):1001–9. https://doi.org/10.1194/jlr.M200489-JLR200.

    Article  CAS  PubMed  Google Scholar 

  90. Pullinger CR, Eng C, Salen G, Shefer S, Batta AK, Erickson SK, et al. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest. 2002;110(1):109–17. https://doi.org/10.1172/JCI15387.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  91. Fiorucci S, Cipriani S, Baldelli F, Mencarelli A. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res. 2010;49(2):171–85. https://doi.org/10.1016/j.plipres.2009.11.001.

    Article  CAS  PubMed  Google Scholar 

  92. Fiorucci S, Mencarelli A, Palladino G, Cipriani S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci. 2009;30(11):570–80. https://doi.org/10.1016/j.tips.2009.08.001.

    Article  CAS  PubMed  Google Scholar 

  93. Kern F Jr. Epidemiology and natural history of gallstones. Semin Liver Dis. 1983;3(2):87–96. https://doi.org/10.1055/s-2008-1040675.

    Article  PubMed  Google Scholar 

  94. Salen G, Nicolau G, Shefer S, Mosbach EH. Hepatic cholesterol metabolism in patients with gallstones. Gastroenterology. 1975;69(3):676–84.

    CAS  PubMed  Google Scholar 

  95. Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun. 2002;298(5):714–9.

    Article  CAS  PubMed  Google Scholar 

  96. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003;278(11):9435–40. https://doi.org/10.1074/jbc.M209706200.

    Article  CAS  PubMed  Google Scholar 

  97. Maruyama T, Tanaka K, Suzuki J, Miyoshi H, Harada N, Nakamura T, et al. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. J Endocrinol. 2006;191(1):197–205. https://doi.org/10.1677/joe.1.06546.

    Article  CAS  PubMed  Google Scholar 

  98. Poole DP, Godfrey C, Cattaruzza F, Cottrell GS, Kirkland JG, Pelayo JC et al. Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterol Motil 2010;22(7):814–25, e227–8. doi:https://doi.org/10.1111/j.1365-2982.2010.01487.x, e228.

    Article  CAS  Google Scholar 

  99. Keitel V, Reinehr R, Gatsios P, Rupprecht C, Gorg B, Selbach O, et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology. 2007;45(3):695–704. https://doi.org/10.1002/hep.21458.

    Article  CAS  PubMed  Google Scholar 

  100. Keitel V, Ullmer C, Haussinger D. The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes. Biol Chem. 2010;391(7):785–9. https://doi.org/10.1515/BC.2010.077.

    Article  CAS  PubMed  Google Scholar 

  101. Khurana S, Raufman JP, Pallone TL. Bile acids regulate cardiovascular function. Clin Transl Sci. 2011;4(3):210–8. https://doi.org/10.1111/j.1752-8062.2011.00272.x.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  102. Keitel V, Donner M, Winandy S, Kubitz R, Haussinger D. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun. 2008;372(1):78–84. https://doi.org/10.1016/j.bbrc.2008.04.171.

    Article  CAS  PubMed  Google Scholar 

  103. Yang JI, Yoon JH, Myung SJ, Gwak GY, Kim W, Chung GE, et al. Bile acid-induced TGR5-dependent c-Jun-N terminal kinase activation leads to enhanced caspase 8 activation in hepatocytes. Biochem Biophys Res Commun. 2007;361(1):156–61. https://doi.org/10.1016/j.bbrc.2007.07.001.

    Article  CAS  PubMed  Google Scholar 

  104. Giaretta PR, Suchodolski JS, Blick AK, Steiner JM, Lidbury JA, Rech RR. Distribution of bile acid receptor TGR5 in the gastrointestinal tract of dogs. Histol Histopathol. 2018:18025. https://doi.org/10.14670/HH-18-025.

  105. Keitel V, Haussinger D. TGR5 in the biliary tree. Dig Dis. 2011;29(1):45–7. https://doi.org/10.1159/000324127.

    Article  CAS  PubMed  Google Scholar 

  106. Shaham O, Wei R, Wang TJ, Ricciardi C, Lewis GD, Vasan RS, et al. Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol. 2008;4:214. https://doi.org/10.1038/msb.2008.50.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  107. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10(3):167–77. https://doi.org/10.1016/j.cmet.2009.08.001.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  108. Brighton CA, Rievaj J, Kuhre RE, Glass LL, Schoonjans K, Holst JJ, et al. Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled bile acid receptors. Endocrinology. 2015;156(11):3961–70. https://doi.org/10.1210/en.2015-1321.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  109. Kuhre RE, Wewer Albrechtsen NJ, Larsen O, Jepsen SL, Balk-Moller E, Andersen DB, et al. Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas. Mol Metab. 2018;11:84–95. https://doi.org/10.1016/j.molmet.2018.03.007.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  110. Carino A, Cipriani S, Marchiano S, Biagioli M, Scarpelli P, Zampella A, et al. Gpbar1 agonism promotes a Pgc-1alpha-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice. Sci Rep. 2017;7(1):13689. https://doi.org/10.1038/s41598-017-13102-y.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  111. Velazquez-Villegas LA, Perino A, Lemos V, Zietak M, Nomura M, Pols TWH, et al. TGR5 signalling promotes mitochondrial fission and beige remodelling of white adipose tissue. Nat Commun. 2018;9(1):245. https://doi.org/10.1038/s41467-017-02068-0.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  112. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439(7075):484–9. https://doi.org/10.1038/nature04330.

    Article  CAS  PubMed  Google Scholar 

  113. Perino A, Pols TW, Nomura M, Stein S, Pellicciari R, Schoonjans K. TGR5 reduces macrophage migration through mTOR-induced C/EBPbeta differential translation. J Clin Invest. 2014;124(12):5424–36. https://doi.org/10.1172/JCI76289.

    Article  PubMed Central  PubMed  Google Scholar 

  114. Pols TW, Nomura M, Harach T, Lo Sasso G, Oosterveer MH, Thomas C, et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 2011;14(6):747–57. https://doi.org/10.1016/j.cmet.2011.11.006.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  115. Alemi F, Kwon E, Poole DP, Lieu T, Lyo V, Cattaruzza F, et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest. 2013;123(4):1513–30. https://doi.org/10.1172/JCI64551.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  116. Lieu T, Jayaweera G, Zhao P, Poole DP, Jensen D, Grace M, et al. The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice. Gastroenterology. 2014;147(6):1417–28. https://doi.org/10.1053/j.gastro.2014.08.042.

    Article  CAS  PubMed  Google Scholar 

  117. Vassileva G, Golovko A, Markowitz L, Abbondanzo SJ, Zeng M, Yang S, et al. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochem J. 2006;398(3):423–30. https://doi.org/10.1042/BJ20060537.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  118. Briere DA, Ruan X, Cheng CC, Siesky AM, Fitch TE, Dominguez C, et al. Novel small molecule agonist of TGR5 possesses anti-diabetic effects but causes gallbladder filling in mice. PLoS One. 2015;10(8):e0136873. https://doi.org/10.1371/journal.pone.0136873.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  119. Li T, Holmstrom SR, Kir S, Umetani M, Schmidt DR, Kliewer SA, et al. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Mol Endocrinol. 2011;25(6):1066–71. https://doi.org/10.1210/me.2010-0460.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  120. Donepudi AC, Boehme S, Li F, Chiang JY. G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice. Hepatology. 2017;65(3):813–27. https://doi.org/10.1002/hep.28707.

    Article  CAS  PubMed  Google Scholar 

  121. Adams TD, Davidson LE, Litwin SE, Kolotkin RL, LaMonte MJ, Pendleton RC, et al. Health benefits of gastric bypass surgery after 6 years. JAMA. 2012;308(11):1122–31. https://doi.org/10.1001/2012.jama.11164.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  122. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, et al. Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. The N Engl J Med. 2014;370(21):2002–13. https://doi.org/10.1056/NEJMoa1401329.

    Article  CAS  PubMed  Google Scholar 

  123. Ding L, Sousa KM, Jin L, Dong B, Kim BW, Ramirez R, et al. Vertical sleeve gastrectomy activates GPBAR-1/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice. Hepatology. 2016;64(3):760–73. https://doi.org/10.1002/hep.28689.

    Article  CAS  PubMed  Google Scholar 

  124. Ryan KK, Tremaroli V, Clemmensen C, Kovatcheva-Datchary P, Myronovych A, Karns R, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014;509(7499):183–8. https://doi.org/10.1038/nature13135.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  125. Bhutta HY, Rajpal N, White W, Freudenberg JM, Liu Y, Way J, et al. Effect of Roux-en-Y gastric bypass surgery on bile acid metabolism in normal and obese diabetic rats. PLoS One. 2015;10(3):e0122273. https://doi.org/10.1371/journal.pone.0122273.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  126. Gerhard GS, Styer AM, Wood GC, Roesch SL, Petrick AT, Gabrielsen J, et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care. 2013;36(7):1859–64. https://doi.org/10.2337/dc12-2255.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  127. Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring). 2009;17(9):1671–7. https://doi.org/10.1038/oby.2009.102.

    Article  CAS  Google Scholar 

  128. Pournaras DJ, Glicksman C, Vincent RP, Kuganolipava S, Alaghband-Zadeh J, Mahon D, et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology. 2012;153(8):3613–9. https://doi.org/10.1210/en.2011-2145.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  129. Simonen M, Dali-Youcef N, Kaminska D, Venesmaa S, Kakela P, Paakkonen M, et al. Conjugated bile acids associate with altered rates of glucose and lipid oxidation after Roux-en-Y gastric bypass. Obes Surg. 2012;22(9):1473–80. https://doi.org/10.1007/s11695-012-0673-5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  130. Steinert RE, Peterli R, Keller S, Meyer-Gerspach AC, Drewe J, Peters T, et al. Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial. Obesity (Silver Spring). 2013;21(12):E660–8. https://doi.org/10.1002/oby.20522.

    Article  CAS  Google Scholar 

  131. Kohli R, Bradley D, Setchell KD, Eagon JC, Abumrad N, Klein S. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab. 2013;98(4):E708–12. https://doi.org/10.1210/jc.2012-3736.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  132. Kohli R, Setchell KD, Kirby M, Myronovych A, Ryan KK, Ibrahim SH, et al. A surgical model in male obese rats uncovers protective effects of bile acids post-bariatric surgery. Endocrinology. 2013;154(7):2341–51. https://doi.org/10.1210/en.2012-2069.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  133. Flynn CR, Albaugh VL, Cai S, Cheung-Flynn J, Williams PE, Brucker RM, et al. Bile diversion to the distal small intestine has comparable metabolic benefits to bariatric surgery. Nat Commun. 2015;6:7715. https://doi.org/10.1038/ncomms8715 https://www.nature.com/articles/ncomms8715#supplementary-information.

    Article  CAS  PubMed  Google Scholar 

  134. Myronovych A, Salazar-Gonzalez RM, Ryan KK, Miles L, Zhang W, Jha P, et al. The role of small heterodimer partner in nonalcoholic fatty liver disease improvement after sleeve gastrectomy in mice. Obesity (Silver Spring). 2014;22(11):2301–11. https://doi.org/10.1002/oby.20890.

    Article  CAS  Google Scholar 

  135. Habegger KM, Al-Massadi O, Heppner KM, Myronovych A, Holland J, Berger J, et al. Duodenal nutrient exclusion improves metabolic syndrome and stimulates villus hyperplasia. Gut. 2014;63(8):1238–46. https://doi.org/10.1136/gutjnl-2013-304583.

    Article  CAS  PubMed  Google Scholar 

  136. Kohli R, Kirby M, Setchell KD, Jha P, Klustaitis K, Woollett LA, et al. Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity-related comorbidities. Am J Physiol Gastrointest Liver Physiol. 2010;299(3):G652–60. https://doi.org/10.1152/ajpgi.00221.2010.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  137. Hao Z, Leigh Townsend R, Mumphrey MB, Gettys TW, Yu S, Munzberg H, et al. Roux-en-Y gastric bypass surgery-induced weight loss and metabolic improvements are similar in TGR5-deficient and wildtype mice. Obes Surg. 2018. https://doi.org/10.1007/s11695-018-3297-6.

    Article  PubMed  PubMed Central  Google Scholar 

  138. Zhai H, Li Z, Peng M, Huang Z, Qin T, Chen L, et al. Takeda G protein-coupled receptor 5-mechanistic target of rapamycin complex 1 signaling contributes to the increment of glucagon-like peptide-1 production after Roux-en-Y gastric bypass. EBioMedicine. 2018;32:201–14. https://doi.org/10.1016/j.ebiom.2018.05.026.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences, Cornell University, T3 014A Veterinary Research Tower, Ithaca, NY, 14853, USA

    Karolina E. Zaborska & Bethany P. Cummings

Authors
  1. Karolina E. Zaborska
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bethany P. Cummings
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bethany P. Cummings.

Ethics declarations

Conflict of Interest

Karolina E. Zaborska and Bethany P. Cummings declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Pathogenesis of Type 2 Diabetes and Insulin Resistance

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zaborska, K.E., Cummings, B.P. Rethinking Bile Acid Metabolism and Signaling for Type 2 Diabetes Treatment. Curr Diab Rep 18, 109 (2018). https://doi.org/10.1007/s11892-018-1092-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11892-018-1092-3

Keywords

Search

Navigation